Quell Therapeutics Advances Multinational CHILL Trial for CAR-Treg Therapy

A LinkedIn post from Quell Therapeutics highlights recent progress in its CHILL Phase 1/2 trial for QEL-005, a CAR-Treg therapy targeting refractory rheumatoid arthritis and systemic sclerosis. The post notes the initiation of two additional U.K. clinical sites at University Hospitals Birmingham and Royal Free London, bringing the total initiated sites in the country to six.

The post further indicates that additional trial sites in Germany and Spain are preparing for initiation following European Clinical Trial Application approval in April, and that active recruitment is underway across the multinational basket study. For investors, this suggests operational momentum in Quell’s lead program, progression toward broader patient enrollment, and potential value inflection as early safety and efficacy data from QEL-005 begin to emerge in competitive autoimmune and cell therapy markets.